Exploring the Effectiveness of an Experimental Class of Drug
Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?
Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?
A clinical trial tests the effectiveness of an approved colon cancer drug against advanced pancreatic neuroendocrine cancer.
A clinical trial for patients with BRCA mutations uses a PARP inhibitor as part of the maintenance chemotherapy experimental treatment.
A clinical trial tests whether a malaria drug can make standard chemotherapy for advanced pancreatic cancer more effective.
A clinical trial compares two chemotherapy regimens to see which one is more effective at knocking out remaining cancer cells.
For patients with stable metastatic pancreatic cancer, a clinical trial compares standard chemotherapy with immunotherapy.
A clinical trial seeks pancreatic cancer patients with the MSI (microsatellite instability) genetic signature, to test an immunotherapy drug.
A clinical trial uses a new immunotherapy drug in combination with standard chemotherapy drugs in metronomic therapy to treat metastatic pancreatic cancer.
Gene therapy combined with standard first-line chemotherapy treatment forms a clinical trial for metastatic pancreatic cancer.
Exploring the effectiveness of the immunotherapy combination of cancer vaccines and a checkpoint blockade drug against metastatic pancreatic cancer.